This cohort study provided evidence supporting the association of tirzepatide treatment, compared to GLP-1 receptor agonists, with lower hazards of all-cause mortality and adverse CV or kidney events through a head-to-head comparison in patients with type 2 diabetes, Vin-Cent Wu, MD, PhD, attending physician in the department of internal medicine at National Taiwan University Hospital, and colleagues wrote These insights advocate for the integration of tirzepatide into therapeutic strategies for managing type 2 diabetes and highlight its potential to enhance current clinical practice. Wu and colleagues analyzed data from the TriNetX U.S
See more comments To view or add a comment, sign in More Relevant Posts This exchange, and the comments beneath it, provide insight into why our approach to pharmaceutical development is so costly and broken
Enhanced Energy and Quality of Life: Many patients report feeling more energetic, motivated, and confident as their health improves
No controlled study has tested either protocol in humans, and no study has compared them head-to-head
& Gong, Z
.png.jpg)
